Bristol-Myers Squibb Co. Earnings: What's Next for the Drugmaker?

Bristol-Myers Squibb stock has hit decade highs lately, with promising drug candidates inspiring investors to greater confidence. But will Bristol-Myers Squibb earnings follow suit? Find out here.

Jan 23, 2014 at 7:00PM

Bristol-Myers Squibb (NYSE:BMY) will release its quarterly report on Friday, and the stock has already built in strong expectations about the drug developer's future, rising to their best levels since the early 2000s. Yet even though the company has worked to focus on its most lucrative potential treatment areas, Bristol-Myers will still have to contend with Merck (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), and other pharma giants in developing blockbuster drugs that can outcompete those of its rivals.

Bristol-Myers Squibb has done a great job over the past year in finding growth opportunities, with promising work in diabetes and other high-profile areas. But more recently, the company has looked at narrowing in on specific categories of drugs, including cancer treatments and immunotherapy. That transformation could help Bristol-Myers grow earnings even faster, but it still leaves the company open to plenty of competition. Let's take an early look at what's been happening with Bristol-Myers Squibb over the past quarter and what we're likely to see in its report.

Stats on Bristol-Myers Squibb

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$4.30 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can Bristol-Myers earnings turn back upward?
In recent months, analysts have gotten nervous about the long-term potential for Bristol-Myers Squibb earnings, reducing their full-year 2014 projections by $0.17 per share. That hasn't stopped the stock's rise, though, with gains of 11% since mid-October.

Bristol-Myers Squibb's third-quarter earnings report was reasonably strong, with sales climbing 9% despite the ongoing impact of the loss of patent protection on former blockbuster drug Plavix. Bristol-Myers has seen success from some of its newer drugs, with skin-cancer treatment Yervoy's sales climbing 33% during the quarter. Moreover, international growth has been solid, with sales up 18% internationally despite pressure from a wide-ranging Chinese probe of several pharmaceutical companies that has had a big impact on sales throughout the industry.


Source:, Flickr.

But the real driver for Bristol-Myers has been promising drug results and strategic moves. In late October, the company said that its nivolumab treatment for non-small cell lung cancer produced impressive survival results, encouraging an analyst upgrade of the stock. Moreover, Bristol-Myers became the first company to submit an all-oral hepatitis C treatment regimen for approval in Japan, following phase 3 data supporting the combination of its daclatasvir and asunaprevir drugs. In light of Gilead's lead in the hepatitis C space with its Sovaldi all-oral treatment, Bristol-Myers' victory in Japan was substantial, and it's working with Merck on a potential new combination therapy as well.

Bristol-Myers has made a huge strategic bet, though, with the sale last month of its stake in its diabetes treatment prospects to AstraZeneca (NYSE:AZN). The move will allow Bristol-Myers to focus more on cancer drugs as well as its antiviral immunotherapies and some specialty drugs, but it ups the ante in forcing the company to fend off its competitors in those areas in order to succeed. Still, given the highly competitive diabetes market, Bristol-Myers might be better able to thrive in its remaining business areas without having to deal with the distraction of the highly dynamic diabetes-treatment area, where the FDA has been increasingly stringent in requiring costly trials.

In the Bristol-Myers earnings report, watch for the company to give a more detailed picture of its strategy after divesting its diabetes business. With more resources to dedicate to its remaining focus areas, Bristol-Myers Squibb needs to establish its ability to produce growth from its best prospects now and in the future.

Another way to profit from promising treatments
The best way to play the pharma and biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Bristol-Myers Squibb to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information